CXCL9 and ovarian carcinoma: Expanding prior reports already suggesting involvement of CXCR3 chemokines in the ICB mechanism of action, our study is, to the best of our knowledge, the first to demonstrate that CXCL9 is all by itself sufficient to overcome ICB resistance in ovarian cancer.